Sanofi India Issues Notice for Transfer of Unclaimed Shares to IEPF Authority

Sanofi India Limited has issued a public notice regarding the mandatory transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority for shareholders who have not claimed their dividends for seven consecutive years or more. Regulatory Compliance Notice The company has published newspaper advertisements on March 14, 2026, in Business Standard (English) and Sakal (Marathi) newspapers, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This notice addresses shareholders whose shares are liable for transfer to the IEPF as per Section 124(6) of the Companies Act, 2013. Transfer Requirements and Timeline Under the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, companies must transfer all shares to the IEPF demat account where dividends have remained unclaimed for seven consecutive years or more. Key Details: Information Notice Date: March 13, 2026 Publication Date: March 14, 2026 Deadline for Claims: June 13, 2026 Starting Period: Final dividend for FY 2018 Affected Dividends: All subsequent declared dividends Sanofi India has sent separate communications dated March 13, 2026, to all affected shareholders who have not encashed their final dividend for financial year 2018 and subsequent dividends declared by the company. Shareholder Action Required Shareholders are requested to forward requisite documents to either the company or its Registrar and Transfer Agent, MUGF Intime India Private Limited (formerly Link Intime India Private Limited), to claim unclaimed dividend amounts and shares. A comprehensive list of shareholders who have not encashed dividends for seven consecutive years is available on the company's website. Recovery Process for Transferred Shares Once shares are transferred to IEPF, all future benefits will be issued in favor of the IEPF Authority. However, shareholders can reclaim both unclaimed dividends and transferred shares by: Making an online application in prescribed e-form IEPF-5 Obtaining an entitlement letter from the company Submitting required documents as enumerated in the e-form Following the procedure outlined on the IEPF website at www.iepf.gov.in Contact Information For queries related to this matter, shareholders can contact: Contact Details: Information Registrar: MUGF Intime India Private Limited Address: C-101, Embassy 247, L.B.S Marg, Vikhroli (West), Mumbai - 400 083 Phone: +91 81081 16767 Email: investor.helpdesk@in.mpms.mugf.com The notice emphasizes that no claims will be entertained against the company once shares are transferred to IEPF, making it crucial for eligible shareholders to act before the June 13, 2026 deadline. Sanofi India Limited has released the complete transcript of its investor/analysts call held on February 26, 2026, discussing financial results for Q4FY26 and the year ended December 2025. The pharmaceutical company submitted the transcript to stock exchanges on March 5, 2026, following the earlier upload of the video recording. Regulatory Compliance and Documentation The transcript submission was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Haresh Vala, Company Secretary & Compliance Officer (Membership No: A18246), and digitally authenticated on March 5, 2026, at 15:31:40 +05'30'. Parameter: Details Call Date: February 26, 2026 Call Time: 4:00 pm Discussion Topic: Q4FY26 and FY25 Financial Results Period Covered: Quarter and year ended December 31, 2025 Transcript Submission: March 5, 2026 Recording Location: Company website - Analyst/Investor Meet section Management Participation The investor conference call was attended by key management personnel including Mr. Deepak Arora (Managing Director), Mr. Rachid Ayari (Whole-Time Director and Chief Financial Officer), and Mr. Haresh Vala (Company Secretary). The call was moderated and included a comprehensive Q&A session with investors and analysts. Key Discussion Areas The transcript reveals detailed discussions on the company's business transformation journey, financial performance, and strategic initiatives. Management highlighted the pivotal transformation undertaken to modernize the business model, positioning the company as an R&D-driven, AI-enabled biopharma organization with focus on patient centricity and digital capabilities. Business Segment: Performance Highlights Diabetes Portfolio: Plus 6% growth in insulin overall for full year Q4 Performance: 11% growth in diabetes segment Partnership Business: Stabilizing with growth expectations Market Position: Lantus maintains 31% market leadership in basal segment Accessibility and Transparency Both the video recording and transcript are now available on Sanofi India's official website in the Analyst/Investor Meet section, ensuring comprehensive access to stakeholders. This dual documentation approach demonstrates the company's commitment to transparency and regulatory compliance in investor communications. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.